AOD-9604: The Fat-Loss Peptide — What the Evidence Actually Shows

AOD-9604 is one of the most-marketed and least-clinically-supported peptides in the consumer market. It is sold by online peptide vendors as a "targeted fat-loss" or "lipolytic" peptide. It is sometimes recommended by clinics that operate at the margins of the regulatory framework. It is occasionally compounded by pharmacies that should not be compounding it.

The actual story of AOD-9604 is a cautionary tale about the gap between mechanistic hypothesis and clinical translation. The compound was developed, tested in humans, failed its key trial, and was abandoned by its sponsor — yet remains in circulation 15+ years later. The marketing claims have outrun the data substantially.

This post is the honest evidence review.

What AOD-9604 is

AOD-9604 stands for "Anti-Obesity Drug 9604." It is a synthetic 16-amino-acid peptide corresponding to amino acids 176-191 of human growth hormone — the C-terminal fragment of the larger GH molecule. The naming convention reflects its origin and intended indication.

The mechanistic hypothesis: full-length human growth hormone has both anabolic effects (muscle building, lean mass support) and lipolytic effects (fat breakdown). The downside of giving full-length GH is the systemic anabolic burden — insulin resistance, edema, joint pain, carpal tunnel, possible cancer risk concerns. The hypothesis behind AOD-9604 was that the C-terminal fragment retained the lipolytic effect without the anabolic burden.

This is, on its face, a reasonable hypothesis. Different segments of large protein hormones often retain partial functionality. The hypothesis was worth testing.

It was tested. The hypothesis did not hold up.

The development history

AOD-9604 was developed by Metabolic Pharmaceuticals, an Australian biotech, in the late 1990s. The compound progressed through:

• Preclinical (animal) studies — supportive. Rodent models showed dose-dependent lipolysis and reduction in body fat at supraphysiologic doses.
• Phase 1 (safety) trials — successful. The compound was well-tolerated in human subjects.
• Phase 2a (efficacy signal) trial — modestly supportive. Showed some signal on lipolysis biomarkers in human subjects.
• Phase 2b (definitive efficacy) trial — the trial that mattered. A 12-week, randomized, placebo-controlled study in obese subjects (n approximately 500). The trial failed to demonstrate weight-loss efficacy distinguishable from placebo.¹

After the phase 2b failure, Metabolic Pharmaceuticals discontinued the obesity development program. The compound was subsequently licensed to other entities for various indications (including osteoarthritis) but never advanced through phase 3 in any indication and never reached FDA approval.

The phase 2b failure is the key fact. A 12-week, n=500, placebo-controlled trial is the proper test of a weight-loss compound. The trial was negative. The compound does not produce clinically meaningful weight loss in humans at the tested doses and duration.

How AOD-9604 ended up in consumer markets anyway

Several pathways:

1. Australian Therapeutic Goods Administration (TGA) supplement listing

In the early 2010s, AOD-9604 was listed in Australia as a dietary supplement ingredient by some manufacturers. The listing was a regulatory categorization, not an efficacy endorsement, and was later removed. Some peptide-marketing material still references this listing as if it were an approval. It was not.

2. US "research peptide" market

The compound is sold by online vendors as a research peptide, labeled "not for human consumption." Same framework that governs every research-grade peptide: the disclaimer is the seller's legal protection, the buyer's clinical use is the buyer's risk. We cover this framework in our post on why research peptide vendors emphasize the prohibition.

3. Compounding outside the framework

Some compounding pharmacies have prepared AOD-9604 for clinics — typically anti-aging clinics, hormone-optimization clinics, or weight-loss clinics operating at the margins of the framework. This is not legitimate 503A compounding because AOD-9604 does not meet the eligibility criteria (not a component of an approved drug, no USP monograph, not on the bulk drug substances list). The pharmacies doing it are operating outside the regulatory framework, regardless of how their marketing describes them. Full framework explained in the 503A bulk drug substances list explainer.

4. Marketing inertia

The compound has been marketed as a "targeted fat-loss peptide" for 15+ years. Marketing materials, peptide-clinic websites, biohacker forums, and consumer-supplement sites have built up a cumulative body of optimistic claims that survive independent of any clinical evidence. The marketing claims now circulate as if they were established facts.

What the evidence actually shows

Sorting the literature by quality:

Strong evidence (large RCT in humans):

• The phase 2b obesity trial — negative for weight loss.

Weak evidence (small human studies, biomarker endpoints):

• Phase 1 and 2a trials showed some signal on lipolysis biomarkers (free fatty acid release, glycerol levels) at the doses tested. These are mechanistic signals, not clinical-outcome signals.
• Small studies in osteoarthritis showed mixed results.

Animal evidence:

• Multiple rodent obesity models show dose-dependent lipolysis and body-fat reduction at supraphysiologic doses.
• Translation to humans is the open question, and the human trial answered it negatively.

Mechanism literature:

• The hypothesized lipolytic mechanism via beta-3 adrenergic-like receptor signaling has supportive cell-line data.
• Whether the mechanism operates at clinically relevant doses in humans is the question the phase 2b trial answered negatively.

The honest summary: AOD-9604 may have measurable biological effects on lipid metabolism at high doses in laboratory settings. It does not produce clinically meaningful weight loss in humans. The compound failed its definitive trial 15+ years ago.

What about anecdotal user reports?

Anecdotal reports from consumers using AOD-9604 (typically combined with diet, exercise, sometimes other peptides) describe weight loss outcomes. The anecdotes are real. The attribution is the problem.

When a user injects AOD-9604, simultaneously implements a caloric deficit, increases exercise, and adds resistance training, weight loss occurs. The user attributes the weight loss to the AOD-9604. The same weight loss would have occurred from the diet and exercise alone. The placebo-controlled trial isolated the AOD-9604 contribution from the lifestyle contribution. The AOD-9604 contribution was indistinguishable from zero.

This is the standard problem with consumer-peptide self-experimentation: the active intervention (lifestyle) gets the credit assigned to the inactive intervention (the peptide).

The regulatory state in 2026

• FDA approval: None, in any indication.
• Active clinical development: None at any meaningful scale.
• 503A compounding eligibility: Not eligible (fails all three criteria).
• USP monograph: None.
• Bulk drug substances list: Not listed.

The compound exists in a regulatory zone outside the legitimate pharmaceutical framework. It cannot be legally prescribed by US-licensed clinicians and compounded by US-licensed pharmacies in a way that complies with FDA rules. Operations that do so are doing so in violation.

What patients should do instead

If the underlying goal is fat loss (and specifically loss of fat without loss of lean mass), the evidence-based intervention set is:

1. Caloric deficit through dietary protein anchor. 1.6-2.2g protein per kg of goal weight per day; total calories appropriate to produce 0.5-1% weekly weight loss.

2. Resistance training. 2-3 sessions per week, compound movements, progressive overload. Signals which muscle to preserve during weight loss. Covered in detail in our lean-mass preservation protocol.

3. GLP-1 medication, if clinically appropriate. For patients meeting clinical criteria for obesity pharmacotherapy, prescribed compounded semaglutide or tirzepatide produces clinically meaningful weight loss in placebo-controlled trials at the same dose levels.

4. Sleep, stress, and recovery. The non-glamorous interventions that determine whether the protocol actually works.

The combination of dietary protein + resistance training + GLP-1 (when appropriate) + sleep is the evidence-based fat-loss protocol. AOD-9604 has no place in that protocol because the evidence for it does not exist at the level required.

TelePeptide's position

TelePeptide does not prescribe AOD-9604. The compound is outside the legitimate compounding framework, has failed its definitive human trial, and provides no clinical benefit beyond what evidence-based interventions already deliver. We will not prescribe it under any circumstances regardless of patient request.

This is the same position we hold on BPC-157, TB-500, retatrutide (until approved), MariTide (until approved), and all other compounds outside the eligibility framework. The full framework is covered in our compounded investigational peptides post.

Bottom line

AOD-9604 is a peptide that failed its definitive human trial in obesity 15+ years ago, has no FDA approval in any indication, is not eligible for legitimate 503A compounding, and has been marketed as a "targeted fat-loss" peptide for so long that the marketing has outlived the actual evidence. Real fat loss in humans comes from caloric deficit, dietary protein, resistance training, and (when clinically appropriate) GLP-1 medication. No peptide produces "targeted fat loss" because no such mechanism exists in human physiology at the doses and routes consumer peptides use. Save the money. Use what works.

Footnotes

1. AOD-9604 phase 2b clinical trial results, Metabolic Pharmaceuticals disclosures, 2005-2007. ↩